reference standard comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-03-12. Numbers and descriptions here follow the published literature rather than marketing material.
序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。
Semaglutide 是一种经结构修饰的胰高血糖素样肽-1 类似物，其主链与内源性 GLP-1(7-36) 约有百分之九十四的序列一致性。第 8 位丙氨酸被 α-氨基异丁酸取代，使二肽基肽酶-4 无法识别原有切割位点。第 34 位赖氨酸换为精氨酸，进一步降低酶解速率。第 26 位赖氨酸经间隔基连接一条含十八个碳的二酸脂肪链，该侧链赋予分子与血浆白蛋白结合的能力。
该分子作为 GLP-1 受体的选择性激动剂发挥作用，受体属于 B 类 G 蛋白偶联受体家族，激活后经 Gs 通路提升细胞内环腺苷酸水平。在胰腺 β 细胞，信号促进葡萄糖依赖性的胰岛素释放，血糖偏低时该作用明显减弱。在胰岛 α 细胞，胰高血糖素分泌受到抑制。中枢神经系统与胃肠道同样存在受体表达，相应信号参与食欲调节以及胃排空速率的降低。
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
| Property | Value | Notes |
|---|---|---|
| 分子式 | C187H291N45O59 | 按主链与 C18 二酸侧链计算 |
| 分子量 | 约 4113.6 道尔顿 | 游离碱形式，随反离子略有差异 |
| 外观 | 白色至类白色冻干粉末 | 具吸湿性，需干燥保存 |
| 溶解性 | 微溶于水，易溶于碱性缓冲液 | 溶解性随 pH 升高而改善 |
| 等电点 | 约 5.4 | 影响缓冲液选择与聚集倾向 |
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Lyophilized peptide material is typically stored at or below -20 °C, with -80 °C used for longer-term archives. Vials should remain sealed and desiccated because moisture promotes aggregation and hydrolysis. Repeated freeze-thaw cycles are avoided since they can alter peptide conformation and reduce recovery. Once reconstituted, solutions are generally kept at 2-8 °C and used within a defined window. Stability beyond those windows depends on buffer composition and concentration, and exact limits are product-specific rather than universal.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities by hydrophobicity. Mass spectrometry confirms molecular weight and detects truncation or modification products. Peptide mapping after enzymatic digestion verifies the amino acid sequence. Quantitation is often performed by LC-MS/MS or by immunoassay, and the two approaches can give different values because they measure different things. Method validation parameters such as accuracy, precision, and limit of quantitation are reported alongside results.
Certificate of analysis documents from suppliers typically report purity by chromatographic area, water content, and counter-ion identity. Independent verification is advisable because reported values can be generated under differing conditions. Impurity profiles matter for research use, where aggregates, deamidation products, and residual solvents may influence experimental results. Container, lot, and chain-of-custody records support traceability. Analytical results are method-dependent, so comparisons between laboratories require the same procedure and reference standards.
=== Recoded synthetic genome === One way to achieve the encoding of multiple unnatural amino acids is by synthesising a rewritten genome. In 2010, at the cost of $40 million an organism, Mycoplasma laboratorium, was constructed that was controlled by a synthetic, but not recoded, genome. The first genetically recoded organism was created by a collaboration between George Church's and Farren Isaacs' labs, when the wild type E. coli MG1655 was recoded in such a way that all 321 known UAG stop codons were substituted with synonymous UAA codons and release factor 1 was knocked out in order to eliminate the interaction with the exogenous stop codon and improve unnatural protein synthesis. In 2019, Escherichia coli Syn61 was created, with a 4 megabase recoded genome consisting of only 61 codons instead of the natural 64. In addition to the elimination of the usage of rare codons, the specificity of the system needs to be increased as many tRNA recognise several codons
denotes contact. The second assumption in contact mechanics is related to the fact, that no tension force is allowed to occur within the contact area (contacting bodies can be lifted up without adhesion forces). This leads to an inequality which the stresses have to obey at the contact interface. It is formulated for the normal stress
In common with many other developed countries, Canada is experiencing an increase in healthcare expenditures due to a demographic shift toward an older population, with more retirees and fewer people of working age. In 2021, the average age in Canada was 41.9 years. Life expectancy is 81.1 years. A 2016 report by the chief public health officer found that 88 percent of Canadians, one of the highest proportions of the population among G7 countries, indicated that they "had good or very good health". Eighty percent of Canadian adults self-report having at least one major risk factor for chronic disease: smoking, physical inactivity, unhealthy eating or excessive alcohol use. Canada has one of the highest rates of adult obesity among OECD countries, contributing to approximately 2.7 million cases of diabetes. Four chronic diseases—cancer (leading cause of death), cardiovascular diseases, respiratory diseases, and diabetes—account for 65 percent of deaths in Canada. There are approximately 8 million people aged 15 and older with one or more disabilities in Canada. In 2024, the Canadian Institute for Health Information estimated that healthcare spending reached $372 billion, or 12.4 percent of Canada's GDP for that year. In 2022, Canada's per-capita spending on health expenditures ranked 12th among health-care systems in the OECD. The Commonwealth Fund's 2021 report comparing the healthcare systems of the 11 most developed countries ranked Canada second-to-last.
From the mid-19th century to the 1930s, American physicians prescribed Cannabis sativa as a prescription drug for various medical conditions. In the 1960s, the counterculture movement introduced the use of psychoactive drugs, including cannabis. Young adults and college students reported the recreational prevalence of cannabis, among other drugs, at 20-25% while the cultural mindset of using was open and curious. In 1969, the FBI reported that between the years 1966 and 1968, the number of arrests for marijuana possession, which had been outlawed throughout the United States under Marijuana Tax Act of 1937, had increased by 98%. Despite acknowledgement that drug use was greatly growing among America's youth during the late 1960s, surveys have suggested that only as much as 4% of the American population had ever smoked marijuana by 1969. By 1972, however, that number would increase to 12%. That number would then double by 1977. The Controlled Substances Act of 1970 classified marijuana along with heroin and LSD as a Schedule I drug, i.e., having the relatively highest abuse potential and no accepted medical use. Most marijuana at that time came from Mexico, but in 1975 the Mexican government agreed to eradicate the crop by spraying it with the herbicide paraquat, raising fears of toxic side effects. Colombia then became the main supplier. The "zero tolerance" climate of the Reagan and Bush administrations (1981–1993) resulted in passage of strict laws and mandatory sentences for possession of marijuana.
Sources: en.wikipedia.org
N-Methyltryptamine (NMT), also known as monomethyltryptamine, is a chemical compound of the tryptamine family and a naturally occurring compound found in various plants and animals, including humans. It is biosynthesized in humans from tryptamine by certain N-methyltransferase enzymes, such as indolethylamine N-methyltransferase. It is a known component of human urine. NMT is an alkaloid derived from L-tryptophan that has been found in the bark, shoots and leaves of several plant genera, including Virola, Acacia, Mimosa, and Desmanthus—often together with the related compounds N,N-dimethyltryptamine (DMT) and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT). NMT acts as a serotonin receptor agonist and serotonin releasing agent and is said to produce hallucinogenic effects in humans.
The Claisen-Schmidt condensation between 3-(methoxymethoxy)benzaldehyde [13709-05-2] (1) and cyclohexanone (2) afforded CID:54364197 (3). Michael addition of dimethylamine leads the aminoketone, i.e. 2-[dimethylamino-[3-(methoxymethoxy)phenyl]methyl]cyclohexan-1-one, CID21518320. Reduction of the ketone proceeds stereospecifically to afford the cis aminoalcohol [51356-58-2] (4). Mild hydrolysis of the product gives the free phenol ciramadol (5).
Maui Mallard in Cold Shadow – originally released as Donald in Maui Mallard (Japanese: Donald Duck no Maui Mallard (ドナルドダックのマウイマラード)) – is a platforming video game developed and published by Disney Interactive. The game was released in Europe in November 1995, and in Brazil in spring 1997 for the Sega Mega Drive. It was also ported by Eurocom Entertainment Software to the SNES and released in North America in January 1997, in Europe mostly in autumn 1996 (although the SNES version was released in Germany at the end of 1995), and in Japan on December 20, 1996. A Microsoft Windows port was released in North America in November 1996. It was ported one last time to the Game Boy by Bonsai Entertainment Corp., released in North America in August 1998. The game stars Donald Duck in a metafictional role as duck detective Maui Mallard (a spoof of 1980s Hawaii-based TV detective, Magnum P.I. in name and appearance), who adopts the name "Cold Shadow" when he dresses up in ninja garb. In the North American versions of the game, all Donald Duck references are absent, and the protagonist is instead referred to as "Maui Mallard," as, according to composer Patrick Collins, the marketing team felt Donald Duck wasn't cool in the United States. Although the end of the game informed the player to look forward to Maui's next adventure, the planned sequel was cancelled. The game was rereleased on the Steam and GOG digital storefronts on May 17, 2019.
Sources: en.wikipedia.org
== Bibliography == Barkawi, Tarak (April 2006). "Culture and Combat in the Colonies: The Indian Army In the Second World War". Journal of Contemporary History. 41 (2). Sage: 325–355. doi:10.1177/0022009406062071. S2CID 145364543. Barthorp, Michael (2002). Afghan Wars and the North-West Frontier 1839–1947. London: Cassel. ISBN 0-304-36294-8. Barua, Pradeep (2003). Gentlemen of the Raj: The Indian Army Officer Corps, 1817–1949. Westport, CT: Praegar. ISBN 0275979997. Chandler, David (2002). Oxford History of the British Army (2nd ed.). USA: Oxford University Press. ISBN 0192803115. Gaylor, John (1996). Sons of John Company – The Indian & Pakistan Armies 1903–1991. Tunbridge Wells, Kent: Parapress. ISBN 1-898594-41-4. Haythornthwaite, P.J. (1992). The World War One Sourcebook. Arms and Armour Press. Heathcote, T. A. (1974). The Indian Army – The Garrison of British Imperial India, 1822–1922. Newton Abbot, Devon: David & Charles. Ilbert, Courtenay (1 January 1913). "British India". Journal of the Society of Comparative Legislation. 13 (2): 327–333. JSTOR 752287. Imperial Gazetteer of India, Volume IV (1908). Indian Empire: Administrative. Oxford: Clarendon Press. p. 552. Jackson, Donovan (1940). India's Army. London: Sampson Low. Lapping, Brian (1985). End of Empire. London: Guild Publishing. Mazumder, Rajit K. (2003). The Indian army and the making of Punjab. Delhi, India: Permanent Black. ISBN 8178240599. Nathan, R.; Lee-Warner, William; Carnduff, H. W. C.; Maclagan, E. D.; Walker, G. H. D.; Collen, Edwin; Nathan; Bythel, W. J.; Hemming, T. H. (1908).
== Function == Phosphorylation of a protein by GSK-3 usually inhibits the activity of its downstream target. GSK-3 is active in a number of central intracellular signaling pathways, including cellular proliferation, migration, glucose regulation, and apoptosis. GSK-3 was originally discovered in the context of its involvement in regulating glycogen synthase. After being primed by casein kinase 2 (CK2), glycogen synthase gets phosphorylated at a cluster of three C-terminal serine residues, reducing its activity. In addition to its role in regulating glycogen synthase, GSK-3 has been implicated in other aspects of glucose homeostasis, including the phosphorylation of insulin receptor IRS1 and of the gluconeogenic enzymes phosphoenolpyruvate carboxykinase and glucose 6 phosphatase. However, these interactions have not been confirmed, as these pathways can be inhibited without the up-regulation of GSK-3. GSK-3 has also been shown to regulate immune and migratory processes. GSK-3 participates in a number of signaling pathways in the innate immune response, including pro-inflammatory cytokine and interleukin production. The inactivation of GSK3B by various protein kinases also affects the adaptive immune response by inducing cytokine production and proliferation in naïve and memory CD4+ T cells.
The main Imperial Russian Army was commanded by Field Marshal Michael Andreas Barclay de Tolly, who recognized that Napoleon's immediate goal was a decisive battle to crush the main Russian force in the west. In response, the Russian army used scorched-earth tactics as it withdrew east, and harried the Grande Armée with light Cossack cavalry. The Grande Armée did not adjust its operational methods in response. Provisioning such an enormous army with adequate food and fresh water had proven difficult since the very start of the campaign, exacerbated by the sparse terrain of western Russia; diseases such as typhus and dysentery rapidly became rampant among the rank and file. These factors led to most of the losses of the main column of the Grande Armée, which in one case amounted to 95,000 men, including deserters, in a week. The main Russian army retreated for almost three months. This constant retreat led to the increasing unpopularity of Barclay de Tolly (who was a Baltic German and already mistrusted by the Russian elite) and a respected Russian veteran, Prince Mikhail Kutuzov, was made the new Commander-in-Chief by Tsar Alexander. Finally, the two armies engaged in the Battle of Borodino on 7 September, in the vicinity of Moscow. The battle was the largest and bloodiest single-day action of the Napoleonic Wars, involving more than 250,000 men and resulting in at least 70,000 casualties. The battle was indecisive; the French captured the main positions on the battlefield but failed to destroy the Russian army.
Sources: en.wikipedia.org
差别集中在三处：第 8 位残基被非天然氨基酸取代，第 34 位换成精氨酸，第 26 位增加一条脂肪酸侧链。前两处改动降低酶解速率，侧链则通过白蛋白结合延长循环时间。综合结果是半衰期从约两分钟延长到约一周。
胰岛素释放需要细胞内环腺苷酸与钙信号升高，同时依赖葡萄糖代谢产生的协同信号。血糖水平较低时协同信号不足，分泌增强有限。这一机制在降糖效果与低血糖风险之间提供了缓冲。
白蛋白结合是主要原因，它减少肾小球滤过并保护分子免受蛋白酶降解。序列修饰带来的酶解抵抗同样不可忽略，二者共同作用。脂肪链的疏水性还会影响组织分布，但其对总半衰期的贡献程度仍在研究之中。
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.